Tradjenta 01
Tradjenta Tablet, Film Coated
Product Images NDC 0597-0140
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tradjenta (NDC 0597-0140). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Boehringer Ingelheim Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Tradjenta 02
This appears to be a table displaying the percentage of patients with an event and the number of patients at risk in a clinical trial involving a placebo group and a group treated with a drug called Linagliptin. However, without additional context or information, it is difficult to determine the specific details or implications of this data.*
Tradjenta 03
This table shows a comparison between Linagliptin and Glimepiride in terms of the percentage of patients that experienced an event. Unfortunately, there is not enough information regarding what type of event is being referred to.*
Tradjenta 04
Tradjenta 05
This is a description of a medication called Tradjenta (linagliptin) available in tablet form with a dosage of 5 mg per tablet. It is taken on a daily basis. The packaging includes 10 blister cards of 10 tablets each, making a total of 100 tablets in a package. There is a warning that the package is not child-resistant. The text also includes information on the manufacturer and the NDC codes for the medication.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
